Will mRNA Technology Companies Spawn Innovation Ecosystems?

Publikation: Bidrag til tidsskriftTidsskriftartikel

Standard

Will mRNA Technology Companies Spawn Innovation Ecosystems? / Grimpe, Christoph; Minssen, Timo; Price II, William Nicholson; Stern, Ariel.

I: Harvard Business Review, 18.04.2022.

Publikation: Bidrag til tidsskriftTidsskriftartikel

Harvard

Grimpe, C, Minssen, T, Price II, WN & Stern, A 2022, 'Will mRNA Technology Companies Spawn Innovation Ecosystems?', Harvard Business Review. <https://hbr.org/2022/04/will-mrna-technology-companies-spawn-innovation-ecosystems>

APA

Grimpe, C., Minssen, T., Price II, W. N., & Stern, A. (2022). Will mRNA Technology Companies Spawn Innovation Ecosystems? Harvard Business Review. https://hbr.org/2022/04/will-mrna-technology-companies-spawn-innovation-ecosystems

Vancouver

Grimpe C, Minssen T, Price II WN, Stern A. Will mRNA Technology Companies Spawn Innovation Ecosystems? Harvard Business Review. 2022 apr. 18.

Author

Grimpe, Christoph ; Minssen, Timo ; Price II, William Nicholson ; Stern, Ariel. / Will mRNA Technology Companies Spawn Innovation Ecosystems?. I: Harvard Business Review. 2022.

Bibtex

@article{4fcb33bf8cfe476ca1a4e9d04dbd91fc,
title = "Will mRNA Technology Companies Spawn Innovation Ecosystems?",
abstract = "The mRNA technologies that helped rapidly create effective Covid-19 vaccines could become technology platform businesses, which has tremendous implications for players the world of drug development. These platforms could attract other companies interested in exploiting their advantages to develop other drugs. But all the stakeholders — platform owners, external pharmaceutical and biotech companies, policymakers, and regulators — will have to make a variety of choices.",
keywords = "Faculty of Law, platform economy, management, Vaccines, regulation, Intellectual property, Open innovation, collaboration",
author = "Christoph Grimpe and Timo Minssen and {Price II}, {William Nicholson} and Ariel Stern",
year = "2022",
month = apr,
day = "18",
language = "English",
journal = "Harvard Business Review",
issn = "0017-8012",
publisher = "Harvard Business School Publishing",

}

RIS

TY - JOUR

T1 - Will mRNA Technology Companies Spawn Innovation Ecosystems?

AU - Grimpe, Christoph

AU - Minssen, Timo

AU - Price II, William Nicholson

AU - Stern, Ariel

PY - 2022/4/18

Y1 - 2022/4/18

N2 - The mRNA technologies that helped rapidly create effective Covid-19 vaccines could become technology platform businesses, which has tremendous implications for players the world of drug development. These platforms could attract other companies interested in exploiting their advantages to develop other drugs. But all the stakeholders — platform owners, external pharmaceutical and biotech companies, policymakers, and regulators — will have to make a variety of choices.

AB - The mRNA technologies that helped rapidly create effective Covid-19 vaccines could become technology platform businesses, which has tremendous implications for players the world of drug development. These platforms could attract other companies interested in exploiting their advantages to develop other drugs. But all the stakeholders — platform owners, external pharmaceutical and biotech companies, policymakers, and regulators — will have to make a variety of choices.

KW - Faculty of Law

KW - platform economy

KW - management

KW - Vaccines

KW - regulation

KW - Intellectual property

KW - Open innovation

KW - collaboration

M3 - Journal article

JO - Harvard Business Review

JF - Harvard Business Review

SN - 0017-8012

ER -

ID: 279498395